A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against COVID-19. In a new study published in mBio, an open-access journal of the American Society for Microbiology, researchers provide further proof of this by showing that mumps IgG titers, or levels of IgG antibody, are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with the MMR II vaccine produced by Merck. MMR II contains the Edmonston strain of measles, the Jeryl Lynn (B-level) strain of mumps, and the Wistar RA 27/3 strain of rubella.
A new study led by Australia's national science agency CSIRO, has found 95.5 per cent of current entries in GISAID, the world's largest novel coronavirus genome database, do not contain relevant patient information -- a critical piece of the puzzle to understand the virus and how it is evolving.
A recent paper examines a mutation of the spike protein of SARS-CoV-2 that has been observed to have arisen independently twice.
Pfizer and BioNTech have today announced their new vaccine candidate (BNT162b2) is 90% effective against SARS-CoV-2.
A genetically edited form of a herpes simplex virus -- rewired to keep it from taking refuge in the nervous system and eluding an immune response -- has outperformed a leading vaccine candidate in a new study from the University of Cincinnati, Northwestern University and the University of Nebraska-Lincoln.
A new nanoparticle vaccine candidate developed for the novel coronavirus creates virus-neutralizing antibodies in mice at levels that are 10 times higher than is observed in individuals, who have recovered from the COVID-19 disease.
A person will acquire immunity to a specific disease when T cells develop into memory cells after making contact with pathogens.
Until recently, it was believed that the innate immune system, the body's first line of defense, lacked the ability to remember pathogens like the adaptive immune system.
The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody response that is relatively stable for at least five months, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 28, in the journal Science.
Scientists at Fred Hutchinson Cancer Research Center in Seattle have shown that a potent antibody from a COVID-19 survivor interferes with a key feature on the surface of the coronavirus's distinctive spikes and induces critical pieces of those spikes to break off in the process.
Humans have different susceptibilities to SARS-CoV-2, and eventually develop varying degrees of fatigue, fever, and breathing problems.
An experimental vaccine, designed to enlist the body's own immune system to target cancer cells, has shown promise for treating and preventing cancer in mice.
The coronavirus, responsible for the COVID-19 pandemic, has one official name--SARS-CoV-2. But according to virologists, mutations lead to hundreds of genetically-distinct versions of the virus.
New research from an immunology team at the University of Chicago may shed light on the challenges of developing a universal flu vaccine that would provide long-lasting and broad protection against influenza viruses.
SPIN (SPermidin and eugenol INtegrator for the contrasting incidence of coronavirus in EU population) is a European project powered by EIT Food that is currently developing a dietary supplement supporting the function of the immune system in the fight against SARS-CoV-2 infections in the population at high risk.
Prostate cancer is the most common type of cancer among American men after skin cancer, but the disease does not affect all races equally.
Knowing you have developed antibodies against the SARS-CoV-2 virus after recovering from COVID-19 doesn't tell you everything about your immunity.
Chemist Mahmoud Moradi has received a $422,579 grant from the National Institutes of Health to advance his work modeling hemagglutinin, the critical protein of the influenza virus.
Researchers with the U.S. Army Futures Command are part of a team that tested alternative ways to measure COVID-19 antibody levels, resulting in a process that is faster, easier and less expensive to use on a large scale. Their method holds promise for accurately identifying potential donors who have the best chance of helping infected patients through convalescent plasma therapy.
Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies.